Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Claret L et al. – The modeling framework successfully predicted survival in a phase III trial on the basis of capecitabine phase II data in CRC. It is a useful tool to support end–of–phase II decisions and design of phase III studies.

Related Articles

Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09    Relevance Score: 72%

Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk
Cancer Causes and Control, 10/02/09    Relevance Score: 72%

P73 expression and its clinical significance in colorectal cancer
Colorectal Disease, 10/19/09    Relevance Score: 71%

trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II
Cancer Causes and Control, 10/28/09    Relevance Score: 70%

Association of clinicopathological features with UbcH10 expression in colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09    Relevance Score: 70%

Today in Colorectal Cancer/Polyps...keeping you current

Radiotherapy in the Treatment of Resectable Rectal Adenocarcinoma
American Journal of Clinical Oncology, 12/07/09

Metastatic colorectal cancer: recent advances in its clinical management
Expert Review of Anticancer Therapy, 12/07/09

Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy
Pathology International, 12/07/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address